Head of Regulatory Affairs Regulatory strategy development, submission management, and global market access for medical device organizations. Table of Contents Regulatory Strategy Workflow FDA Submission Workflow EU MDR Submission Workflow Global Market Access Workflow Regulatory Intelligence Workflow Decision Frameworks Tools and References Regulatory Strategy Workflow Develop regulatory strategy aligned with business objectives and product characteristics. Workflow: New Product Regulatory Strategy Gather product information: Intended use and indications Device classification (risk level) Technology platform Target markets and timeline Identify applicable regulations per target market: FDA (US): 21 CFR Part 820, 510(k)/PMA/De Novo EU: MDR 2017/745, Notified Body requirements Other markets: Health Canada, PMDA, NMPA, TGA Determine optimal regulatory pathway: Compare submission types (510(k) vs De Novo vs PMA) Assess predicate device availability Evaluate clinical evidence requirements Develop regulatory timeline with milestones Estimate resource requirements and budget Identify regulatory risks and mitigation strategies Obtain stakeholder alignment and approval Validation: Strategy document approved; timeline accepted; resources allocated Regulatory Pathway Selection Matrix Factor 510(k) De Novo PMA Predicate Available Yes No N/A Risk Level Low-Moderate Low-Moderate High Clinical Data Usually not required May be required Required Review Time 90 days (MDUFA) 150 days 180 days User Fee ~$22K (2024) ~$135K ~$440K Best For Me-too devices Novel low-risk High-risk, novel Regulatory Strategy Document Template REGULATORY STRATEGY Product: [Name] Version: [X.X] Date: [Date] 1. PRODUCT OVERVIEW Intended use: [One-sentence statement of intended patient population, body site, and clinical purpose] Device classification: [Class I / II / III] Technology: [Brief description, e.g., "AI-powered wound-imaging software, SaMD"] 2. TARGET MARKETS & TIMELINE | Market | Pathway | Priority | Target Date | |--------|----------------|----------|-------------| | USA | 510(k) / PMA | 1 | Q1 20XX | | EU | Class [X] MDR | 2 | Q2 20XX | 3. REGULATORY PATHWAY RATIONALE FDA: [510(k) / De Novo / PMA] — Predicate: [K-number or "none"] EU: Class [X] via [Annex IX / X / XI] — NB: [Name or TBD] Rationale: [2–3 sentences on key factors driving pathway choice] 4. CLINICAL EVIDENCE STRATEGY Requirements: [Summarize what each market needs, e.g., "510(k): bench + usability; EU Class IIb: PMCF study"] Approach: [Literature review / Prospective study / Combination] 5. RISKS AND MITIGATION | Risk | Prob | Impact | Mitigation | |------------------------------|------|--------|-----------------------------------| | Predicate delisted by FDA | Low | High | Identify secondary predicate now | | NB audit backlog | Med | Med | Engage NB 6 months before target | 6. RESOURCE REQUIREMENTS Budget: $[Amount] Personnel: [FTEs] External: [Consultants / CRO] FDA Submission Workflow Prepare and submit FDA regulatory applications. Workflow: 510(k) Submission Confirm 510(k) pathway suitability: Predicate device identified (note K-number, e.g., K213456) Substantial equivalence (SE) argument supportable on intended use and technological characteristics No new intended use or technology concerns triggering De Novo Schedule and conduct Pre-Submission (Q-Sub) meeting if needed (see Pre-Sub Decision ) Compile submission package checklist: Cover letter with device name, product code, and predicate K-number Section 1: Administrative information (applicant, contact, 510(k) type) Section 2: Device description — include photos, dimensions, materials list Section 3: Intended use and indications for use Section 4: Substantial equivalence comparison table (see example below) Section 5: Performance testing — protocols, standards cited, pass/fail results Section 6: Biocompatibility summary (ISO 10993-1 risk assessment, if patient contact) Section 7: Software documentation (IEC 62304 level, cybersecurity per FDA guidance, if applicable) Section 8: Labeling — final draft IFU, device label Section 9: Summary and conclusion Conduct internal review and quality check against FDA RTA checklist Prepare eCopy per FDA format requirements (PDF bookmarked, eCopy cover page) Submit via FDA ESG portal with user fee payment Monitor MDUFA clock and respond to AI/RTA requests within deadlines Validation: Submission accepted; MDUFA date received; tracking system updated Substantial Equivalence Comparison Example Characteristic Predicate (K213456) Subject Device Same? Notes Intended use Wound measurement Wound measurement ✓ Identical Technology 2D camera 2D + AI analysis ✗ New TC; address below Energy type Non-energized Non-energized ✓ Patient contact No No ✓ SE conclusion New TC does not raise new safety/effectiveness questions; bench data demonstrates equivalent accuracy (±2mm vs ±3mm predicate) Workflow: PMA Submission Confirm PMA pathway: Class III device or no suitable predicate Clinical data strategy defined Complete IDE clinical study if required: IDE approval Clinical protocol execution Study report completion Conduct Pre-Submission meeting Compile PMA submission checklist: Volume I: Administrative, device description, manufacturing Volume II: Nonclinical studies (bench, animal, biocompatibility) Volume III: Clinical studies (IDE protocol, data, statistical analysis) Volume IV: Labeling Volume V: Manufacturing information, sterilization Submit original PMA application Address FDA questions and deficiencies Prepare for FDA facility inspection Validation: PMA approved; approval letter received; post-approval requirements documented FDA Submission Timeline Milestone 510(k) De Novo PMA Pre-Sub Meeting Day -90 Day -90 Day -120 Submission Day 0 Day 0 Day 0 RTA Review Day 15 Day 15 Day 45 Substantive Review Days 15–90 Days 15–150 Days 45–180 Decision Day 90 Day 150 Day 180 Common FDA Deficiencies and Prevention Category Common Issues Prevention Substantial Equivalence Weak predicate comparison; no performance data Build SE table with data column; cite recognized standards Performance Testing Incomplete protocols; missing worst-case rationale Follow FDA-recognized standards; document worst-case justification Biocompatibility Missing endpoints; no ISO 10993-1 risk assessment Complete ISO 10993-1 matrix before testing Software Inadequate hazard analysis; no cybersecurity bill of materials IEC 62304 compliance + FDA cybersecurity guidance checklist Labeling Inconsistent claims vs. IFU; missing symbols standard Cross-check label against IFU; cite ISO 15223-1 for symbols See: references/fda-submission-guide.md EU MDR Submission Workflow Achieve CE marking under EU MDR 2017/745. Workflow: MDR Technical Documentation Confirm device classification per MDR Annex VIII Select conformity assessment route based on class: Class I: Self-declaration Class IIa/IIb: Notified Body involvement Class III: Full NB assessment Select and engage Notified Body (for Class IIa+) — see selection criteria below Compile Technical Documentation per Annex II checklist: Annex II §1: Device description, intended purpose, UDI Annex II §2: Design and manufacturing information (drawings, BoM, process flows) Annex II §3: GSPR checklist — each requirement mapped to evidence (standard, test report, or justification) Annex II §4: Benefit-risk analysis and risk management file (ISO 14971) Annex II §5: Product verification and validation (test reports) Annex II §6: Post-market surveillance plan Annex XIV: Clinical evaluation report (CER) — literature, clinical data, equivalence justification Establish and document QMS per ISO 13485 Submit application to Notified Body Address NB questions and coordinate audit Validation: CE certificate issued; Declaration of Conformity signed; EUDAMED registration complete GSPR Checklist Row Example GSPR Ref Requirement Standard / Guidance Evidence Document Status Annex I §1 Safe design and manufacture ISO 14971:2019 Risk Management File v2.1 Complete Annex I §11.1 Devices with measuring function ±accuracy EN ISO 15223-1 Performance Test Report PT-003 Complete Annex I §17 Cybersecurity MDCG 2019-16 Cybersecurity Assessment CS-001 In progress Clinical Evidence Requirements by Class Class Clinical Requirement Documentation I Clinical evaluation (CE) CE report IIa CE with literature focus CE report + PMCF plan IIb CE with clinical data CE report + PMCF + clinical study (some) III CE with clinical investigation CE report + PMCF + clinical investigation Notified Body Selection Criteria Scope: Designated for your specific device category Capacity: Confirmed availability within target timeline Experience: Track record with your technology type Geography: Proximity for on-site audits Cost: Fee structure transparency Communication: Responsiveness and query turnaround See: references/eu-mdr-submission-guide.md Global Market Access Workflow Coordinate regulatory approvals across international markets. Workflow: Multi-Market Submission Strategy Define target markets based on business priorities Sequence markets for efficient evidence leverage: Phase 1: FDA + EU (reference markets) Phase 2: Recognition markets (Canada, Australia) Phase 3: Major markets (Japan, China) Phase 4: Emerging markets Identify local requirements per market: Clinical data acceptability Local agent/representative needs Language and labeling requirements Develop master technical file with localization plan Establish in-country regulatory support Execute parallel or sequential submissions Track approvals and coordinate launches Validation: All target market approvals obtained; registration database updated Market Priority Matrix Market Size Complexity Recognition Priority USA Large High N/A 1 EU Large High N/A 1–2 Canada Medium Medium MDSAP 2 Australia Medium Low EU accepted 2 Japan Large High Local clinical 3 China Large Very High Local testing 3 Brazil Medium High GMP inspection 3–4 Documentation Efficiency Strategy Document Type Single Source Localization Required Technical file core Yes Format adaptation Risk management Yes None Clinical data Yes Bridging assessment QMS certificate Yes (ISO 13485) Market-specific audit Labeling Master label Translation, local requirements IFU Master content Translation, local symbols See: references/global-regulatory-pathways.md Regulatory Intelligence Workflow Monitor and respond to regulatory changes affecting product portfolio. Workflow: Regulatory Change Management Monitor regulatory sources: FDA Federal Register, guidance documents EU Official Journal, MDCG guidance Notified Body communications Industry associations (AdvaMed, MedTech Europe) Assess relevance to product portfolio Evaluate impact: Timeline to compliance Resource requirements Product changes needed Develop compliance action plan Communicate to affected stakeholders Implement required changes Document compliance status Validation: Compliance action plan approved; changes implemented on schedule Regulatory Monitoring Sources Source Type Frequency FDA Federal Register Regulations, guidance Daily FDA Device Database 510(k), PMA, recalls Weekly EU Official Journal MDR/IVDR updates Weekly MDCG Guidance EU implementation As published ISO/IEC Standards updates Quarterly Notified Body Audit findings, trends Per interaction Impact Assessment Template REGULATORY CHANGE IMPACT ASSESSMENT Change: [Description] Source: [Regulation/Guidance] Effective Date: [Date] Assessment Date: [Date] Assessed By: [Name] AFFECTED PRODUCTS | Product | Impact (H/M/L) | Action Required | Due Date | |---------|----------------|------------------------|----------| | [Name] | [H/M/L] | [Specific action] | [Date] | COMPLIANCE ACTIONS 1. [Action] — Owner: [Name] — Due: [Date] 2. [Action] — Owner: [Name] — Due: [Date] RESOURCE REQUIREMENTS: Budget $[X] | Personnel [X] hrs APPROVAL: Regulatory ___ Date _ / Management __ Date ____ Decision Frameworks Pathway Selection and Classification Reference FDA Pathway Selection Is predicate device available? │ Yes─┴─No │ │ ▼ ▼ Is device Is risk level substantially Low-Moderate? equivalent? │ │ Yes─┴─No Yes─┴─No │ │ │ │ ▼ ▼ ▼ ▼ De Novo PMA 510(k) Consider required De Novo or PMA EU MDR Classification Is the device active? │ Yes─┴─No │ │ ▼ ▼ Is it an Does it contact implant? the body? │ │ Yes─┴─No Yes─┴─No │ │ │ │ ▼ ▼ ▼ ▼ III IIb Check Class I contact (measuring/ type sterile if and applicable) duration Pre-Submission Meeting Decision Factor Schedule Pre-Sub Skip Pre-Sub Novel Technology ✓ New Intended Use ✓ Complex Testing ✓ Uncertain Predicate ✓ Clinical Data Needed ✓ Well-established ✓ Clear Predicate ✓ Standard Testing ✓ Regulatory Escalation Criteria Situation Escalation Level Action Submission rejection VP Regulatory Root cause analysis, strategy revision Major deficiency Director Cross-functional response team Timeline at risk Management Resource reallocation review Regulatory change VP Regulatory Portfolio impact assessment Safety signal Executive Immediate containment and reporting Tools and References Scripts Tool Purpose Usage regulatory_tracker.py Track submission status and timelines python regulatory_tracker.py Regulatory Tracker Features: Track multiple submissions across markets Monitor status and target dates Identify overdue submissions Generate status reports Example usage: $ python regulatory_tracker.py --report status Submission Status Report — 2024 -11-01 ┌──────────────────┬──────────┬────────────┬─────────────┬──────────┐ │ Product │ Market │ Type │ Target Date │ Status │ ├──────────────────┼──────────┼────────────┼─────────────┼──────────┤ │ WoundScan Pro │ USA │ 510 ( k ) │ 2024 -12-01 │ On Track │ │ WoundScan Pro │ EU │ MDR IIb │ 2025 -03-01 │ At Risk │ │ CardioMonitor X1 │ Canada │ Class II │ 2025 -01-15 │ On Track │ └──────────────────┴──────────┴────────────┴─────────────┴──────────┘ 1 submission at risk: WoundScan Pro EU — NB engagement not confirmed. References Document Content fda-submission-guide.md FDA pathways, requirements, review process eu-mdr-submission-guide.md MDR classification, technical documentation, clinical evidence global-regulatory-pathways.md Canada, Japan, China, Australia, Brazil requirements iso-regulatory-requirements.md ISO 13485, 14971, 10993, IEC 62304, 62366 requirements Key Performance Indicators KPI Target Calculation First-time approval rate
85% (Approved without major deficiency / Total submitted) × 100 On-time submission 90% (Submitted by target date / Total submissions) × 100 Review cycle compliance 95% (Responses within deadline / Total requests) × 100 Regulatory hold time <20% (Days on hold / Total review days) × 100